Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Top Ten Searches
post partum incontinence fibroid hpv colpotomy ovarian cyst curettage endometriosis intrauterine umbilical cordYour Article Summary
See Latest ArticlesSouthwest Oncology Group Trial S9912: Intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer
Gynecologic Oncology, 06/30/09
Smith HO et al. - Both the overall trial outcome, and specifically the excessively severe systemic toxicity of this regimen would prevent its future development in this exact form. The provocative PFS in a subset of individuals should encourage the development of alternative strategies designed to optimize the delivery of regional therapy in ovarian cancer management.
Related Articles
Preventing future cancers by testing women with ovarian cancer for brca mutations
Journal of Clinical Oncology, 10/22/09
Relevance Score: 72%
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
British Journal of Cancer, 11/02/09
Relevance Score: 70%
Unusual Metals Could Forge New Cancer Drug
ScienceDaily, 10/20/09
Relevance Score: 70%
New Drug Aims To Seek And Destroy Many Types Of Cancer
ScienceDaily, 10/07/09
Relevance Score: 70%
New drug aims to seek and destroy many types of cancer
EurekAlert, 10/06/09
Relevance Score: 70%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Suppression of follicular rupture with meloxicam, a cyclooxygenase-2 inhibitor: potential for emergency contraception
Human Reproduction, 11/24/09
The rationale for mTOR inhibition in epithelial ovarian cancer
Expert Opinion on Investigational Drugs, 11/24/09
Factors contributing to gender differences in serum retinol and -tocopherol in infertile couples
Reproductive BioMedicine Online, 11/24/09
Today in Gynecologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Paracentesis in Ovarian Cancer: A Study of the Physiology during Free Drainage of Ascites
Journal of Palliative Medicine, 11/25/09
How to deal with prognostic factors and radiotherapy results in uterine neoplasms with a sarcomatous component
Clinical and Translational Oncology, 11/25/09
Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer
Cancer, 11/25/09
Sponsor
Article Search
Sponsor